

**Press release**

**28 May 2025**

## **Resolutions of the Annual General Meeting 2025 of Curasight A/S**

**Copenhagen, Denmark, 28 May 2025 – today Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS) held its Annual General Meeting at the office of DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen OE, Denmark**

Today, the shareholders in Curasight passed the following resolutions at the Annual General Meeting in accordance with the agenda:

**1. The Board of Directors' report on the Company's activities in the past financial year**

The general meeting took note of the Board of Directors' report on the Company's activities in 2024.

**2. Presentation and approval of the annual report**

The general meeting adopted the Company's annual report for 2024 unanimously with all votes represented at the general meeting.

**3. Resolution on appropriation of profit or covering of loss as recorded in the adopted annual report**

The general meeting adopted the proposal to carry forward the result for 2024 to the next year according to the adopted annual report for 2024 with all votes represented at the general meeting.

**4. Election of members to the Board of Directors**

The general meeting re-elected Kirsten Aarup Drejer, Lars Trolle, Charlotte Vedel, Andreas Kjær, and Ulrich Krasilnikoff as members of the Board of Directors with consent of all votes represented at the general meeting.

**5. Election of auditor**

PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected as the Company's auditor with consent of all votes represented at the general meeting.

## 6. Proposal from the Board of Director or the shareholders

### 6.1 Incentive Programs

a. Authorisations to issue warrants (Incentive Program for the Board of Directors, the Executive Management and other Key Employees

A proposal from the Board of Directors to authorise the Board of Directors to issue warrants to members of the Board of Directors, to the Executive Board and other Key Employees was unanimously adopted with all votes represented at the general meeting. Consequently, the Company's Articles of Association will be updated to incorporate the following new section 5.2.7:

*"The Company's board of directors is authorised, pursuant to s. 155 of the Danish Companies Act, cf. s. 169 thereof, in one or several instances, to issue up to a total of 7,100,000 warrants to members of the board of directors, the Executive Management and other Key Employees ("Participants") which will entitle the Participants to subscribe for up to a total of nominal DKK 355,000 shares in the Company (corresponding to 10% of the Company's share capital after the expected capital increase) without pre-emption rights for the existing shareholders at a subscription price and allocation determined by the board of directors, provided, however, that the price may not be lower than the market price on the date of the resolution. The market value shall be determined based on the average share price according to Spotlight's official listed share price for the Company's shares during five trading days preceding the date at which allocation of the warrant occurs, or such other price that the Company's board of directors is more reflective of the market price of the shares. The Company's board of directors is also authorised to carry out any related share capital increases, in one or several instances, up to a total of nominally DKK 355,000. The authorization is valid until 28 May 2030. Shares issued pursuant to the authorization in this clause 5.2.7. must be paid up in full, be negotiable instruments, be registered by name and be registered by the name of shareholders in the Company's shareholders' register. The same restrictions on transferability as those applying to the existing shares apply and no shareholder shall be obligated to have the shares redeemed partly or in full. Furthermore, the Company's board of directors is authorised to reuse or reissue lapsed and unexercised warrants, if any, provided that the reuse or reissue occurs under the terms set out in this authorisation."*

### 6.2 Authorisation to the chairman of the meeting

The general meeting adopted a resolution to authorise the chairman of the meeting Ulrik Bangsbo Hansen to apply for registration of the resolutions passed and to make certain amendments, if necessary.

\*\*\*

The Company's new articles of association will be published on the Company's website once they have been registered with the Danish Business Authority, and likewise, the

minutes of the Annual General Meeting will also be made available on the website.

At a board meeting held immediately after the Annual General Meeting, Kirsten Drejer was re-elected as chairman and Lars Trolle vice-chairman of the Board of Directors.

**For more information regarding Curasight, please contact:**

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: [uk@curasight.com](mailto:uk@curasight.com)

[www.curasight.com](http://www.curasight.com)

---

**Curasight** is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.